Research Grants of Prof. Gang Li (Since 2009)
Representative Grants as Principle Investigator (PI)
Funding Source |
Ref. Number |
Duration |
Project Title |
Amount |
|
| Research Grant Council, Hong Kong | 14119115 | 2016.01-2018.12 | Is Smad7 a potential therapeutic target for preventing osteoporotic bone loss? | HK$821,097 | |
| Research Grant Council, Hong Kong | CUHK 470813 | 2014.01-2016.12 | Promote fracture healing by administration of allogenic mesenchymal stem cells (MSCs) | HK$779,429 | |
| Research Grant Council, Hong Kong | 9054014 (N_CityU102/15) | 2016.01-2019.12 | A microarray chip based single cell manipulation system for characterization of electrical stimulation induced stem cell differentiation | HK$400,000 | |
| Research Grant Council, Hong Kong | CUHK 471110 | 2011.01-2013.12 | Functional characterizations of peripheral blood derived mesenchymal stem cells | HK$986,000 | |
| 國家自然科學基金 China Natural Science Fundation | 81172177 | 2012.01-2015.12 | 血管和神经化促进组织工程骨形成的机制研究 Studies of vascularizied and innerviated tissue-enginnered bone: mechansims and applications | RMB 600,000 | |
| 國家自然科學基金 China Natural Science Fundation | 81371946 | 2014.01-2017.12 | SOX11調控骨髓間充質幹細胞分化與遷移的研究及其在骨/軟骨再生中的應用Characterization of Sox-11 gene in MSCs differentiation and migration and its applications in bone and cartilage regeneration | RMB 700,000 | |
| 國家自然科學基金 China Natural Science Fundation | 81172177 | 2012.01-2015.12 | 用胸腺嘧啶激酶基因修飾的間充質幹細胞治療腫瘤的研究 The use of mesenchymal stem cells overexpressing thymidine kinase (TK) as anti-tumor therapy | RMB 550,000 | |
| 國家自然科學基金 China Natural Science Fundation | 30872635 | 2009.01-2011.12 | Study of osteogenic potentials and mechanisms of circulating mesenchymal stem cells | RMB 310,000 | |
深圳市科技創新委員會Shenzhen City Science Innoviaiton Fund |
TBA | 01/01/2016-31/12/2017 |
|
RMB300,000 | |
| 深圳市科技創新委員會Shenzhen City Science Innoviaiton Fund | GJHZ2014 0419120051680 |
21/07/2014-21/07/2016 | 老年人自體脂肪間充質幹細胞移植在骨折癒合中的應用 Adipose tissue derived MSCs from elderly people: their role in promoting fracture healing |
RMB300,000 | |
| 深圳市科技創新委員會Shenzhen City Science Innoviaiton Fund | JCYJ2013 0401171935811 |
2013.10-2015.09 | 系统注射同种异体骨髓间充质干细胞促进骨折愈合的研究 Systemic administraion of allogenic BM-MSCs for promoting fracture helaing | RMB150,000 | |
| Lui Che Woo Institute of Innovation Medicine | CUHK 8303207 | 2013.09-2015.08 | Does the growth factor and mechanical influence tenocyte differentiation through miRNAs? | HK$250,000 | |
| Lui Che Woo Institute of Innovation Medicine | CUHK 8303214 | 2014.03-2016.03 | Phase I clinical trial of autologous bone marrow derived mesenchymal stem cells intra-articular Injection for the treatment of carpal osteoarthritis | HK$250,000 | |
| Hong Kong Innovation Technology Commission | ITS/305/09 | 2010.04-2011.09 | Development of an immortalized human mesenchymal stem cell line overexpressing thymidine kinase (TK) gene for anti-tumor therapy | HK$997,000 | |
Hong Kong Innovation Technology Commission |
InP/045/10 InP/046/10 | 2010.04-2011.09 | Development of an immortalized human mesenchymal stem cell line overexpressing thymidine kinase (TK) gene for anti-tumor therapy | HK$453,600 | |
| Shenyang Xiehe Pharma Company, China | CUHK 7104942 | 2014.09- | Study the effects of Super-antigens on stem cells functions and their applications | HK$800,000 | |
| Hong Kong Cell Engineering Ltd., Co. | CUHK 7010198 | 2012- | Studies of stem cells secretions | HK$300,000 | |
| Amgen Company USA | CUHK 7010165 | 2011.05-2013.08 | Assessment of the anti-angiogenic effect of an antibody on retinopathy-associated neovascularization using oxygen-induced retinopathy model in premature neonatal mice | HK$1,568,805 | |
| Amgen Company USA | CUHK 7010149 | 2011.10-2015.10 | Effect of Sclerostin antibody on osteoporotic fracture healing in rats, and spinal fusion and underline mechanisms | HK$2,702,687 | |
| Eli Lily Co., USA | CUHK 7010124 | 2011.02-2014.12 | Rat/ Mouse osteotomy study, Rabbit/Rat spinal fusion study | HK$1,857,506 | |
| Eli Lily Co., USA | CUHK 7010014 | 2010.03-2014.12 | Animal studies of proprietary bioproduct or small molecules with potential osteogenesis stimulation effect | HK$1,337,910 | |
| Amgen Company USA | CUHK 7001070 | 2009.02-2010.12 | Assessment of time-course effect of an antibody on mouse femoral fracture healing | HK$1,022,468 | |
Funding: I have generated total 43 grants with total finding of approx. HK$32.85 million since 04/2009 till 07/2015 as PI or Co-I (25 grants as PI with funding total approx. of HK$15.80 million). Among which, I have secured 17 competitive grants as PI (including GRF, ITF, NSFC etc.) with funding approx. of HK$7.3 mllion; 18 competitive grants as Co-I with funding approx. of HK$16.75 million; 8 non-competitive grants (mainly for industry contract research) as PI with funding approx. of HK$8.8 million. My average funding (2009-2016) is approx. HK$2,500,000 per year (approx. USD320,000 or GBP 240,000 per year).{Bench marking: In Hong Kong the average funding for a non-clinical professor is about HK$300,000 to 1,000,000 per year. } |
|||||